What is HCA stock price target for 2026?

WallStSmart's 12-month price target for HCA Holdings Inc is $487.91, representing 12.2% upside from the current price of $434.78.

What is HCA stock forecast?

HCA Holdings Inc forecast includes bull, base, and bear case scenarios from 2026 through 2030. Revenue and EPS projections are derived from analyst consensus and conservative extrapolation with growth deceleration for outer years.

Is HCA undervalued based on price targets?

Our DCF intrinsic value for HCA Holdings Inc is $502.29, against a current price of $434.78. The margin of safety is -5.81%.

HCA

HCA Holdings Inc

NYSE: HCA · HEALTHCARE · MEDICAL CARE FACILITIES

$434.78

+0.66% today

Updated 2026-04-29

Market cap

$96.68B

P/E ratio

14.90

P/S ratio

1.27x

EPS (TTM)

$29.02

Dividend yield

0.62%

52W range

$328 – $556

Volume

1.1M

Market cap

$96.68B

P/E ratio

14.90

P/S ratio

1.27x

EPS (TTM)

$29.02

Dividend yield

0.62%

52W range

$328 – $556

Volume

1.1M

HCA Holdings Inc (HCA) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current

$434.78

Consensus

$528.00

+21.44%

2030 Target

$5,143.06

+1082.91%

DCF

$502.29

-5.81% MoS

Current price

$434.78

Analyst consensus

$528.00

+21.44%

2030 Target

$5,143.06

+1082.91%

Intrinsic (DCF)

$502.29

-5.81% MoS

21 analysts:

13 Buy7 Hold1 Sell

Management guidance

No specific CEO revenue guidance found in available data. Management has not provided explicit revenue targets for 2026-2030 period. Company guidance focuses on operational metrics (patient volumes, margin improvement) rather than absolute revenue figures.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range

Bull case (2030)

$8,587.49

$96.5B Rev × 20x P/S

Base case (2030)

$5,143.06

$96.5B Rev × 12x P/S

Bear case (2030)

$3,444.43

$96.5B Rev × 8x P/S

Financial forecast — research-backed

Metric	2023	2024	2025	2026 (E)	2027 (E)	2028 (E)	2029 (E)	2030 (E)
Revenue	$65.0B	$70.6B	$75.6B	$79.4B	$83.3B	$87.5B	$91.8B	$96.5B
Revenue growth	—	8.7%	7.1%	5.1%	4.9%	5.0%	5.0%	5.1%
EPS	$19.03	$21.96	$28.39	$30.53	$33.67	$36.50	$39.50	$42.75
P/S ratio	—	—	—	12.0x	12.0x	12.0x	12.0x	12.0x
Implied price	—	—	—	$4,246.56	$4,435.30	$4,671.22	$4,907.14	$5,143.06

Catalysts & risks

Growth catalysts

+ Aging US population (65+ demographic expanding 3-4% annually)

+ Strategic M&A and de novo hospital/ASC expansions in high-growth states

+ Technology investments and AI/Palantir integration for operational efficiency

+ Market consolidation benefits (scale advantages vs peers)

+ Margin expansion from labor productivity improvements

Key risks

- Medicaid reimbursement pressures and ACA subsidy uncertainties ($250M+ annual impact potential)

- Labor cost inflation and nursing shortages limiting margin growth

- High debt levels (~$156B enterprise value) limiting financial flexibility

- Regulatory/political risk to hospital margins and reimbursement models

- Economic recession reducing elective procedures and patient volumes

Methodology

HCA Holdings Inc's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 21 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 6, 2026.